Skip to main content
. Author manuscript; available in PMC: 2015 Apr 11.
Published in final edited form as: Gene Ther. 2014 Dec 11;22(2):116–126. doi: 10.1038/gt.2014.115

Figure 1.

Figure 1

Increase of Anti-AAV2 Antibodies Pre-Transduction vs. Post-Transduction. (a) Representative sample of fluorescent images taken during in vitro neutralization assay and used to determine the amount of viral transduction in the presence of serum dilutions. Top row: conditions of no serum, 1:500 serum dilution, and 1:10 serum dilution from a monkey before injection of a high dose (> 2×1012 viral genomes) of 7m8 viruses expressing GFP. Bottom row: same conditions following the injection. (b)-(i) Neutralizing antibody titers in serum pre- and post-injection of monkeys administered with (b) wild-type AAV2 capsid, (c) Alternative wild-type AAV capsids, (d) 7m8 capsid, (e) Mutant (tyrosine mutation or 7m8) AAV2 and wild-type AAV2 capsids, (f) Single eye injections of 7m8 or wild-type AAV2 capsids, (g) Double eye injections of mutant (tyrosine mutant or 7m8) AAV2 or wild-type AAV2 capsids, (h) Injection of high viral titers (> 2×1012 viral genomes), or (i) Injection of low viral titers (< 2×1012 viral genomes). Error bars indicate standard deviation (SD) (n=3). y-axis: reciprocal of the serum dilution at which 50% of viral transduction is inhibited in vitro. vg = viral genomes